FUTURE PRODUCTS FROM GENETICS INSTITUTE
Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has been made over the past decade in terms of developing and commercializing its novel protein-based therapeutics.
Commenting in the company's annual report for 1991, president and chief executive Gabriel Schmerge reports that the year was marked by numerous achievements, including the identification and cloning of cytosolic phospholipase A2 (cPLA2), an enzyme which plays a principal role in initiating inflammation.
Syntex, GI's partner in this project, has supported the belief that cPLA2 is fundamentally important in the inflammatory process. Expectations are that products based on this enzyme will be effective in blocking inflammatory reactions that cause tissue destruction in patients with diseases such as rheumatoid arthritis, asthma and psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze